ABCC7 p.Gly85Ala
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 21998193
[PubMed]
Patrick AE et al: "Alteration of CFTR transmembrane span integration by disease-causing mutations."
No.
Sentence
Comment
170
To investigate whether the mutant effects on folding and TM boundaries are caused by the loss of glycine or by the introduction of the ionizable group, the 85 and 91 positions were mutated to the neutral residue alanine (G91A and G85A).
X
ABCC7 p.Gly85Ala 21998193:170:230
status: NEW172 In the ECL-site assay, G91A and G85A N-terminal deletion constructs were glycosylated until a 14-residue deletion was partially glycosylated and a 16-residue deletion was not glycosylated (Figure 6A).
X
ABCC7 p.Gly85Ala 21998193:172:32
status: NEW173 L88 is at the edge of the TM1 ER integration profile edges for both G91A and G85A (Figure 6B), which are shifted by two or three residues from the WT TM1 ER integration profile edge.
X
ABCC7 p.Gly85Ala 21998193:173:77
status: NEW175 The two-residue boundary shifts are consistent with the substitution for glycine causing a small but consistent decreased distance between the ECL1 site and the ER membrane. It is striking that the G85A TM1 glycosylation pattern does not indicate multiple profiles for TM1, indicating that the aberrant pattern of G85E TM1 results from introduction of the glutamate side chain (Figure 6A).
X
ABCC7 p.Gly85Ala 21998193:175:198
status: NEW176 Role of the ionizable side chain in trafficking of G91R and G85E The data from the glycosylation assay demonstrate that the G85E mutant splits the integration profile of TM1, whereas the G91R, G85A, and G91A mutants do not.
X
ABCC7 p.Gly85Ala 21998193:176:193
status: NEW181 However, G85A was not assessed in the Xenopus system.
X
ABCC7 p.Gly85Ala 21998193:181:9
status: NEW182 In stark contrast to G91A, G85A accumulates in the ER, suggesting that both introduction of charge and loss of glycine at position 85 contribute to G85E ER accumulation.
X
ABCC7 p.Gly85Ala 21998193:182:27
status: NEW186 At the lower temperature, both G91R and G85A mutants partially traffic from the ER and are thus temperature sensitive, similar to ΔF508.
X
ABCC7 p.Gly85Ala 21998193:186:40
status: NEW235 HeLa cell trafficking of WT, ΔF508, G85E, G85A, G91R, and G91A mutant CFTR at 37°C was analyzed by Western blot analysis (A).
X
ABCC7 p.Gly85Ala 21998193:235:48
status: NEW240 Figure 6: Experimental TM1 ER luminal integration profile edges for G91A and G85A mutant CFTR.
X
ABCC7 p.Gly85Ala 21998193:240:85
status: NEW241 (A) Core glycosylation analysis of G91A and G85A mutant CFTR containing the artificial ECL1 site by deletion of residues between the glycosylation site and TM1.
X
ABCC7 p.Gly85Ala 21998193:241:44
status: NEW244 (B) A combined schematic of the experimentally identified TM1 ER integration profiles for the G91A and G85A mutants.
X
ABCC7 p.Gly85Ala 21998193:244:103
status: NEW264 Furthermore, the G85A nonpolar mutation does not perturb the TM1 integration profile and continues to cause CFTR ER accumulation.
X
ABCC7 p.Gly85Ala 21998193:264:17
status: NEW269 Experiments designed to test the role of Derlin-1 in the recognition of the G85A mutant would be a reasonable future step toward distinguishing between these two models.
X
ABCC7 p.Gly85Ala 21998193:269:76
status: NEW286 The mutations G91R, G91A, G85E, and G85A were introduced into CFTR constructs containing the natural, artificial, and deletion mutants on the artificial site.
X
ABCC7 p.Gly85Ala 21998193:286:36
status: NEW